Thani Jambulingam, Ph.D.
Areas Taught: Pharmaceutical & Healthcare Marketing
Expertise: Pharmaceutical Marketing Strategies, rug Pricing, Alliances and Acquisitions among Pharmaceutical Companies
Thani Jambulingam, Ph.D., sees challenging years ahead for the pharmaceutical industry, which is the focus of his research and teaching from an array of perspectives.
"Companies are going to have to get more innovative in bringing new products to market and create rich pipelines," he observes. "They are facing pricing and promotional challenges, and the added costs inherent in FDA drug safety standards. Medicare will continue to be a major player affecting the industry."
Currently teaching in both the Executive Pharmaceutical M.B.A. and the undergraduate pharmaceutical marketing programs, he received his master's degree and Ph.D. from the University of Wisconsin, holds an undergraduate degree in pharmacy, and a master's degree in pharmaceutical chemistry. He worked for Glaxo for several years in sales, marketing research, and new product launches, and as a consultant to other major pharmaceutical companies including Abbott, Astra Zeneca, Merck, Pfizer, Wyeth, Novo Nordisk, and Proctor & Gamble. Early in his career, he acquired hands-on experience working as a pharmacist.
Dr. Jambulingam, who studies the pharmaceutical industry within the broader context of the entire health care system, maintains that the industry has a vital role to play in the delivery of better, more efficient, affordable, and safer care. "Each year, 1.5 million people are affected by medical errors. Efforts currently being made to fix this problem carry a $6-7 billion price tag. Pharma has to take an active role in providing information to patients."
His research interests include the entrepreneurial behavior of pharmaceutical firms, product strategies, e-business strategies, the role and impact of alliances and acquisitions on performance, and pricing strategies in the pharmaceutical channel system.